EC Number   |
Application |
Reference |
|---|
   3.4.21.73 | agriculture |
effect of urokinase-type plasminogen activator on in vitro embryo production. Urokinase-type plasminogen activator added to the 18 h in vitro maturation medium significantly increases embryo development rates |
701162 |
| 3.4.21.73 | analysis |
assay of cellular internalization and localization of enzyme:PAI-2 inhibitor complex based on the use of inhibitor labelled with Alexa488 fluorochrome and a polyclonal antibody |
668495 |
| 3.4.21.73 | analysis |
optical zymography technique that specifically detects enzyme activity in biological samples via fluorescence emission at 695 nm. Method can efficiently distinguish the active two-chain enzyme from its proenzyme and directly measure enzyme activities in different cancer cell lines |
667189 |
| 3.4.21.73 | analysis |
quantification of uPA and inhibitor PAI-1 mRNA expression in breast cancer cell lines as well as in tumor tissue of breast cancer patients by sensitive quantitative real-time PCR assays, based on the LightCycler technology. In breast cancer cell lines, mRNA and antigen values are highly correlated for both uPA and PAI-1 I. Correlations between uPA/PAI-1 mRNA and protein in the breast cancer samples were found to be distinctly weaker or not significant. Quantitative determination of mRNA expression for both factors does not mirror antigen levels in breast cancer tissue |
698349 |
| 3.4.21.73 | diagnostics |
expression level of uPA in prostate cancer tissue can be used as a predictor of biochemical recurrence in patients undergoing radical prostatectomy, i.e. strong expression of uPA in addition to a Gleason score, positive surgical margin, and lymph node metastasis |
710656 |
| 3.4.21.73 | diagnostics |
uPA is the strongest single indicator of poor prognosis in patients with metastatic breast cancer |
710469 |
| 3.4.21.73 | diagnostics |
urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer, overview |
708669 |
| 3.4.21.73 | drug development |
complex formation of uPA and uPAR is a target for development of therapeutics |
709570 |
| 3.4.21.73 | drug development |
the enzyme is an attractive target for the development of small molecule active site inhibitors |
683304 |
| 3.4.21.73 | drug development |
uPA is a potential therapeutic target in a variety of pathological conditions, including cancer |
683130 |
